Cephalon Stays Focused On Provigil; ADHD Launch Will Boost Sales Force 40%
Executive Summary
Cephalon expects to increase its sales force by 40% in the second half of 2005 in order to support an upcoming launch of Provigil (modafinil) for pediatric attention deficit hyperactivity disorder
You may also be interested in...
Cephalon Provigil Has 28% Awareness Among Primary Care Physicians
Cephalon will step up its efforts to target primary care physicians in an effort to raise awareness about the sleep disorder agent Provigil (modafinil)
Cephalon Provigil ADHD Trial Failure Cuts Anesta Merger Value By One-Third
Cephalon is experiencing stock hyperactivity disorder following a negative clinical trial report in a preliminary study of Provigil for use in ADHD.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011